cell-based diagnostics | GenomeWeb

cell-based diagnostics

Novacyt will use the financing to accelerate the launch of its NovaPrep system inChinawith its distribution partner Leica Biosystems.

NEW YORK (GenomeWeb) – Fluxion Biosciences said today that it will collaborate with the Stanford University School of Medicine on developing molecular diagnostic tests to identify circulating tumor cells.

A prospective study slated for publication has demonstrated that Precision Therapeutics' ChemoFx test was able to predict whether ovarian cancer patients would live longer if they took a particular chemotherapy.

NEW YORK (GenomeWeb News) – MBio Diagnostics today said that it has achieved ISO 13485:2003 certification for its quality management system.

NEW YORK (GenomeWeb News) – A group of Swiss partners today announced a collaboration to develop, use, and promote a flow cytometry data analysis platform.

NEW YORK (GenomeWeb News) – Oxford Immunotec and Lophius Biosciences said today that they have signed agreements providing each other access to certain intellectual property.

NEW YORK (GenomeWeb News) – Chinese regulators approved Veridex's CellSearch circulating tumor test for aiding in the diagnosis of women with metastatic breast cancer, Veridex announced on Wednesday.

This article has been corrected to note that the OncoTect 3Dx technology is slideless and the sample size for the study is 10,000 rather than the previously stated 100,000.

NEW YORK (GenomeWeb News) – Scientists at Wayne State University will use funding from the National Institutes of Health to conduct genetic studies of human fetal cells with the goal of developing a new diagnostic technology that could enable earlier fetal testing than current methods, the univer

NEW YORK (GenomeWeb News) – BioView and ScreenCell today announced a deal to develop a circulating tumor cell analysis technology.

Pages

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.